Breast Cancer | Current Treatment: Physician Insights | US | 2022
Hormone receptor (HR)-positive / HER2-negative breast cancer has the highest incidence of all breast cancer subtypes. Treatment decisions are influenced by the stage of the disease, the patient’s menopausal status, resectability, the site of metastasis, and treatment history. The FDA’s approval of three CDK4/6 inhibitors in the metastatic setting (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) has changed physicians’ prescribing behavior and created new dynamics in treatment sequencing. This drug class has proven particularly effective when combined with hormonal agents. Additional effective treatments are the PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza and Pfizer’s Talzenna) for metastatic germline BRCA-mutation-positive HER2-negative (including HR-positive) breast cancer and the PI3K inhibitor (Novartis’s Piqray) for advanced PIK3CA-mutation-positive HR-positive / HER2-negative disease.
QUESTIONS ANSWERED
- How are HR-positive / HER2-negative patients mapped in terms of important patient characteristics, such as menopausal status, risk of recurrence, speed of disease progression, and metastatic site?
- According to surveyed physicians, what is the patient share of key drugs and combinations used to treat HR-positive / HER2-negative breast cancer, by line of therapy?
- What are the key drivers and obstacles determining current prescribing of CDK4/6 inhibitors for HR-positive / HER2-negative metastatic breast cancer?
- Where do PARP and PI3K inhibitors fit into the treatment algorithm for HR-positive / HER2-negative disease?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 100 medical oncologists in the United States fielded in June 2022.
Key drugs: Ibrance, Kisqali, Verzenio, Lynparza, Piqray, Talzenna, Afinitor, fulvestrant.
